Tags

Type your tag names separated by a space and hit enter

An open-label, non-randomized comparison of venlafaxine and gabapentin as monotherapy or adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy.
J Pain Res 2010; 3:33-49JP

Abstract

Although many therapies are used in the management of neuropathic pain (NeP) due to polyneuropathy (PN), few comparison studies exist. We performed a prospective, non-randomized, unblended, efficacy comparison of the serotonin-norepinephrine reuptake inhibitor venlafaxine, as either monotherapy or adjuvant therapy, with a first-line medication for NeP, gabapentin, in patients with PN-related NeP. VAS pain scores were assessed after 3 and 6 months in intervention groups and in a cohort of patients receiving no pharmacotherapy. In a total of 223 patients, we analyzed pain quantity and quality (visual analogue scale [VAS] score, Brief Pain Inventory [BPI]), quality of life and health status measures [EuroQol 5 Domains, EQ-5D], Medical Outcomes Sleep Study Scale [MOSSS], Hospital Anxiety and Depression Scale [HADS] and Short Form 36 Health Survey [SF-36]) after 6 months of therapy. Significant improvements in VAS pain scores occurred for all treatment groups after 6 months. Improvements in aspects of daily life and anxiety were identified in all treatment groups. Our data suggest that monotherapy or adjuvant therapy with venlafaxine is comparable to gabapentin for NeP management. We advocate for head-to-head, randomized, double-blinded studies of current NeP therapies.

Authors+Show Affiliations

Department of Clinical Neurosciences and the University of Calgary, Calgary, AB, Canada.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21197308

Citation

Eardley, William, and Cory Toth. "An Open-label, Non-randomized Comparison of Venlafaxine and Gabapentin as Monotherapy or Adjuvant Therapy in the Management of Neuropathic Pain in Patients With Peripheral Neuropathy." Journal of Pain Research, vol. 3, 2010, pp. 33-49.
Eardley W, Toth C. An open-label, non-randomized comparison of venlafaxine and gabapentin as monotherapy or adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy. J Pain Res. 2010;3:33-49.
Eardley, W., & Toth, C. (2010). An open-label, non-randomized comparison of venlafaxine and gabapentin as monotherapy or adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy. Journal of Pain Research, 3, pp. 33-49.
Eardley W, Toth C. An Open-label, Non-randomized Comparison of Venlafaxine and Gabapentin as Monotherapy or Adjuvant Therapy in the Management of Neuropathic Pain in Patients With Peripheral Neuropathy. J Pain Res. 2010 Apr 1;3:33-49. PubMed PMID: 21197308.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An open-label, non-randomized comparison of venlafaxine and gabapentin as monotherapy or adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy. AU - Eardley,William, AU - Toth,Cory, Y1 - 2010/04/01/ PY - 2010/03/31/received PY - 2011/1/4/entrez PY - 2011/1/5/pubmed PY - 2011/1/5/medline KW - gabapentin KW - neuropathic pain KW - peripheral neuropathy KW - pharmacotherapy KW - venlafaxine SP - 33 EP - 49 JF - Journal of pain research JO - J Pain Res VL - 3 N2 - Although many therapies are used in the management of neuropathic pain (NeP) due to polyneuropathy (PN), few comparison studies exist. We performed a prospective, non-randomized, unblended, efficacy comparison of the serotonin-norepinephrine reuptake inhibitor venlafaxine, as either monotherapy or adjuvant therapy, with a first-line medication for NeP, gabapentin, in patients with PN-related NeP. VAS pain scores were assessed after 3 and 6 months in intervention groups and in a cohort of patients receiving no pharmacotherapy. In a total of 223 patients, we analyzed pain quantity and quality (visual analogue scale [VAS] score, Brief Pain Inventory [BPI]), quality of life and health status measures [EuroQol 5 Domains, EQ-5D], Medical Outcomes Sleep Study Scale [MOSSS], Hospital Anxiety and Depression Scale [HADS] and Short Form 36 Health Survey [SF-36]) after 6 months of therapy. Significant improvements in VAS pain scores occurred for all treatment groups after 6 months. Improvements in aspects of daily life and anxiety were identified in all treatment groups. Our data suggest that monotherapy or adjuvant therapy with venlafaxine is comparable to gabapentin for NeP management. We advocate for head-to-head, randomized, double-blinded studies of current NeP therapies. SN - 1178-7090 UR - https://www.unboundmedicine.com/medline/citation/21197308/An_open_label_non_randomized_comparison_of_venlafaxine_and_gabapentin_as_monotherapy_or_adjuvant_therapy_in_the_management_of_neuropathic_pain_in_patients_with_peripheral_neuropathy_ L2 - https://www.dovepress.com/articles.php?article_id=4188 DB - PRIME DP - Unbound Medicine ER -